fast growth continues in Q1; fully-organic sales growth 28%, Rx sales in Germany up 191% and active customers up 0.6 million.
|
EQS-News: Redcare Pharmacy N.V.
/ Key word(s): Development of Sales/Preliminary Results
Redcare Pharmacy: fast growth continues in Q1; fully-organic sales growth 28%, Rx sales in Germany up 191% and active customers up 0.6 million.
Sevenum, the Netherlands, 4 April 2025. Redcare Pharmacy’s preliminary and unaudited sales numbers for the first quarter of the year were published today. The Group reported total sales growth of 28% to EUR 717 million (Q1 2024: EUR 560 million), with both persistently strong growth in non-Rx sales across all countries and rapid Rx sales growth in Germany. Redcare’s active customer base continued to expand at a strong pace in Q1, surpassing the 13 million mark. Redcare Pharmacy’s CEO, Olaf Heinrich comments: “We started the year strongly, achieving excellent results in all our countries. In Germany, the rapid Rx customer growth continued, resulting in Rx sales being up 191% and double-digit quarter-over-quarter.” CFO Jasper Eenhorst adds: “We achieved this persistent fast growth, while successfully improving marketing as a percentage of sales compared to last quarter. As a result, we expect the Q1 EBITDA margin to be back in the positive as planned, and are well on track with our full-year guidance.” Non-Rx sales continued to grow by double-digits, rising 19.7% to EUR 484 million (Q1 2024: EUR 404 million). Rx sales for the Group were up 49.5% to EUR 233 million from EUR 156 million the prior year. Sales in the DACH segment (Germany, Austria and Switzerland) increased by 28.4% in Q1 2025 to EUR 582 million (Q1 2024: EUR 453 million). Non-Rx sales grew 17.3% to EUR 349 million (Q1 2024: EUR 297 million). Rx sales in Germany surpassed EUR 100 million, increasing 191.3% from EUR 37 million in Q1 2024 to EUR 108 million. Sales in the International segment (Belgium, Italy, France, and the Netherlands) grew 26.3% to EUR 135 million (Q1 2024: EUR 107 million). All published figures are preliminary and unaudited. Redcare Pharmacy N.V. will release the full interim report for Q1 2025 on 6 May 2025.
Investor Relations Contact: Monica Ambrosi (Associate Director, Investor Relations) investors@redcare-pharmacy.com
Press Contact: Sven Schirmer (Director, Corporate Communications)
About Redcare Pharmacy. Originally founded in 2001, Redcare Pharmacy N.V. (formerly known as Shop Apotheke Europe N.V.) today is the leading e-pharmacy in Europe, currently active in seven countries: Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland. Headquartered in Sevenum, close to the Dutch city of Venlo and in the heart of Europe, the company has locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven. As the one-stop pharmacy of the future, Redcare Pharmacy offers over 13 million active customers a wide range of more than 250,000 products at attractive and fair prices. Besides OTC, nutritional supplements, beauty and personal care products as well as an extensive assortment of health-related products in all markets, the company also provides prescription drugs for customers in Germany, Switzerland and the Netherlands. Pharmaceutical safety is of top priority. Being a pharmacy at its core, Redcare stands for comprehensive pharmaceutical consultation service. Since care is at the heart of everything Redcare does, the company provides services for all stages of life and health. This ranges from its marketplaces to unique delivery options and medication management. Redcare Pharmacy N.V. has been listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) since 2016. As of 19 June 2023, the company is a member of the MDAX selection index.
04.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Redcare Pharmacy N.V. |
| Erik de Rodeweg 11-13 | |
| 5975 WD Sevenum | |
| Netherlands | |
| Phone: | 0800 - 200 800 300 |
| Fax: | 0800 - 90 70 90 20 |
| E-mail: | investors@redcare-pharmacy.com |
| Internet: | www.redcare-pharmacy.com |
| ISIN: | NL0012044747, DE000A19Y072 |
| WKN: | A2AR94, A19Y072 |
| Indices: | MDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2110926 |
| End of News | EQS News Service |
|
|
2110926 04.04.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.